Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
July 23, 2021

Pfizer and Arvinas to jointly develop and commercialise breast cancer drug

Pfizer and Arvinas have collaborated to co-develop and co-commercialise ARV-471, an investigational oral Protac estrogen receptor protein degrader.

Pfizer and Arvinas to co-develop and co-commercialise breast cancer therapy. Credit: National Cancer Institute on Unsplash.